Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage

Neurocritical Care

Volumn 5, Issue 1, 2006, Pages 71-78

  Wang, Haichen ^a   Gao, Junling ^a,b   Lassiter, Timothy F ^a   McDonagh, David L ^a   Sheng, Huaxin ^a   Warner, David S ^a   Lynch, John R ^a   Laskowitz, Daniel T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NORTH CHINA COAL MEDICAL COLLEGE   (China)

Author keywords

Levetiracetam; Neuroprotection; Posttraumatic epilepsy; Subarachnoid hemorrhage; Traumatic brain injury; Vasospasm

Indexed keywords

ETIRACETAM; FOSPHENYTOIN SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; EPILEPSY; HEAD INJURY; HISTOPATHOLOGY; MALE; MIDDLE CEREBRAL ARTERY; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME; VASOSPASM;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; HEAD INJURIES, CLOSED; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; PIRACETAM; RANDOM ALLOCATION; SUBARACHNOID HEMORRHAGE; TIME FACTORS; VASOSPASM, INTRACRANIAL;

EID: 33748633136     PISSN: 15416933     EISSN: None     Source Type: Journal    
DOI: 10.1385/NCC:5:1:71     Document Type: Article

References (38)

1. Chang BS, Lowenstein DH. Practice parameter: Antiepileptic drug prophylaxis in severe traumatic brain injury. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;60:10-16.
2. Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 1990;323:497-502.
3. Korman LB, Olson MJ. Phenytoin-induced hepatitis, rhabdomyolysis, and renal dysfunction. Clin Pharm 1989;8:514-515.
4. Conger LA, Grabski WJ. Dilantin hypersensitivity reaction. Cutis 1996;57(4):223-226.
5. Patsalos PN. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2(8):473-481.
6. Browne TR, Kugler AR, Eldon MA. Pharmacology and pharmacokinetics of fosphenytoin. Neurology 1996;46(Suppl) 1:S7-S10.
7. Naidech AM, Kreiter KT, Janua N, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke 2005;36:583-587.
8. Klitgaard H, Matagne A, Gobert J, Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998;353:191-206.
9. Dooley M, Plosker GL, Levetiracetam. A review of its adjunctive use in the management of partial onset seizures. Drugs 2000;60:871-893.
10. Mula M, Trimble MR, Yuen A, Liu RS, Sander JW. Psychiatric adverse events during levetiracetam therapy. Neurology 2003;5:704-706.
11. Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002;136:659-672.
12. Hannon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral arteryocclusion model of focal cerebral ischemia. Seizure 2001;10:287-293.
13. Lynch JR, Pineda JA, Morgan D, et al. Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema, Ann Neurol 2002;51:113-117.
14. Lynch JR, Wang H, Mace B, et al. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp Neurol 2005;192:109-116.
15. McGirt MJ, Lynch J, Sheng H, Laskowitz DT, Pearlstein RD, Warner DS. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm following subarachnoid hemorrhage. Stroke 2002;33:2950-2956.
16. Foda MA, Marmarou A. A new model of diffuse brain injury in rats. Part II: morphological characterization. J Neurosurg 1994;80:301-313.
17. Marmarou A, Foda MA, van den Brink W, Campbell J, Kita H, Demetriadou K. A new model of diffuse brain injury in rats. Part I: pathophysiology and biomechanics. J Neurosurg 1994;80:291-300.
18. Schmued LC, Hopkins KJ. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res 2000;874(2):123-130.
19. Parra A, McGirt MJ, Sheng H, Laskowitz DT, Pearlstein RD, Warner DS. Mouse model of subarachnoid hemorrhage associated cerebral vasospasm: Methodological analysis. Neurol Res 2002;24:510-516.
20. Gao J, Wang H, Sheng H, et al. A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage. Neurocritl Care 2006;4:25-31.
21. Hasan D, Schonck RSM, Avezaat CJJ, Tanghe HLJ, van Gijn J. van der Lugt PJM. Epileptic seizures after subarachnoid hemorrhage. Ann Neurol 1993;33:286-291.
22. Rose FC, Sarner M. Epilepsy after ruptured intracranial aneurysm. Brit Med J 1965;5426:18-21.
23. Meek PD, Davis SN, Collins DM, et al. Guidelines for nonemergency use of parenteral phenytoin products: proceedings of an expert panel consensus process. Arch Intern Med 1999;159(22):2639-2644.
24. Rhoney DH, Tipps LB, Murry KR, Basham MC, Michael DB, Coplin WM. Anticonvulsant prophylaxis and timing of seizures after aneurysmal subarachnoid hemorrhage. Neurology 2000;55:258-265.
25. Holtzer CD, Reisner-Keller LA. Phenytoin-induced thrombocytopenia. Ann Pharmacother 1997;31:435-437.
26. Ramsay RE, DeToledo J. Intravenous administration of fosphenytoin: options for the management of seizures. Neurology 1996;46:17-19.
27. Goldstein LB. Potential effects of common drugs on stroke recovery. Arch Neurol 1998;55:454-456.
28. Gidal BE, Baltes E, Otoul C, Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res 2005;64(1-2):1-11.
29. Briggs DE, French JA. Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin Drug Saf 2004;3(5):415-424.
30. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101(26):9861-9866.
31. Crowder KM, Gunther JM, Jones TA, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci USA 1999;96(26):15,268-15,273.
32. Ignarro LJ, Byrns RE, Buga GM, Wood KS. Mechanisms of endothelium-dependent vascular smooth muscle relaxation elicited by bradykinin and VIP. Am J Physiol 1987;253:H1074-H1082.
33. Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens Suppl 1988;6:S188-S191.
34. Ito Y, Isotani E, Mizuno Y, Azuma H, Hirakawa K. Effective improvement of the cerebral vasospasm after subarachnoid hemorrhage with low-dose nitroglycerin. J Cardiovasc Pharmacol 2000;35:45-50.
35. Pluta RM, Oldfield EH, Boock RJ. Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage. J Neurosurg 1997;87:746-751.
36. Wolf EW, Banerjee A, Soble-Smith J, Dohan FC, Jr., White RP, Robertson JT. Reversal of cerebral vasospasm using an intrathecally administered nitric oxide donor. J Neurosurg 1998;89:279-288.
37. Cardile V, Pavone A, Gulino R, Renis M, Scifo C, Perciavalle V. Expression of brain-derived neurotrophic factor(BDNF) and inducible nitric oxide synthase(iNOS) in rat astrocyte cultures treated with Levetiracetam. Brain Res 2003;976(2):227-233.
38. Dagonnier M, Laute MA, Pandolfo M, Manto M. Effects of levetiracetam on the production of nitric oxide - an in vivo study. J Neurol 2005;252(6):727-730.